Arrys Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (NCT03696212) | Arrys Therapeutics | 2019-01-08 |
| Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (NCT03658772) | Arrys Therapeutics | 2018-09-20 |
Track Arrys Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.